It’s been roughly two months since we found out that my first line of cancer treatment had failed and that doctors thought I had about six months to live.
Following this news, we decided to move back to Wichita Falls where we proceeded with second line treatment.
Earlier this week, we found out that there was progression in the tumor, which means that second line treatment had also failed. (╯°□°)╯︵ ┻━┻
Our oncologist at MD Anderson went ahead and prescribed us a set of chemotherapy drugs that will act as a third line of treatment and then referred us to the phase 1 trial group. But, after talking to the phase 1 trial group team, we don’t qualify for phase 1 trials, largely because I had a pulmonary embolism back in May.
In general, we left MD Anderson feeling like there were no other options that they could provide us.
So, what is next?
After talking to Matt Mullenweg, I looked into a few interesting options for continuing treatment. One of these is Omanta, a new company that acts as a dedicated research lab for patients. One of the founders of Omanta worked on Sid Sijbrandij’s team as he went founder mode on cancer.
The goal here is to pull together all of the data at our hands and find therapeutic options that already exist in the form of clinical trials or second line therapies, but that weren’t considered for some reason.
Leave a Reply